311 related articles for article (PubMed ID: 26829647)
1. Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study.
Tugal-Tutkun I; Kadayifcilar S; Khairallah M; Lee SC; Ozdal P; Özyazgan Y; Song JH; Yu HG; Lehner V; de Cordoue A; Bernard O; Gül A
Ocul Immunol Inflamm; 2017 Feb; 25(1):62-70. PubMed ID: 26829647
[TBL] [Abstract][Full Text] [Related]
2. Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study.
Tugal-Tutkun I; Pavesio C; De Cordoue A; Bernard-Poenaru O; Gül A
Ocul Immunol Inflamm; 2018; 26(7):1023-1033. PubMed ID: 29370572
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
4. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
7. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features of patients with Behcet's uveitis].
Liu XS; Gao F; Zhao C; Zhang MF
Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):217-223. PubMed ID: 32187951
[No Abstract] [Full Text] [Related]
11. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
[TBL] [Abstract][Full Text] [Related]
12. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease.
Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Vannozzi L; Franceschini R; Bacherini D; Frediani B; Galeazzi M; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2019; 27(1):58-63. PubMed ID: 28981395
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
[TBL] [Abstract][Full Text] [Related]
14. [Uveitic glaucoma in Behçet's disease: When everything gets complicated].
Belkhadir K; Boutimzine N; Tachfouti S; Laghmari M; Amazouzi A; Cherkaoui O
J Fr Ophtalmol; 2020 Sep; 43(7):635-641. PubMed ID: 32622636
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
Celiker H; Kazokoglu H; Direskeneli H
Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of 85 patients with Behçet's uveitis treated with immunosuppressive agents combined with steroids].
Zhao M; Wang H; Jiao X; Wei WB
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):202-6. PubMed ID: 23866699
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
